Cargando…
The Efficacy of Fimasartan for Cardiovascular Events and Metabolic Syndrome (K-MetS Study): Rationale, Design and Participant Characteristics
Fimasartan, the eighth angiotensin receptor blocker, was launched in March 2011 and was found to have an excellent efficacy and safety profile in a large cross-sectional population study [Safety and Efficacy of Fimasartan in Patients with Arterial Hypertension (Safe-KanArb); Park et al.: Am J Cardio...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315348/ https://www.ncbi.nlm.nih.gov/pubmed/26587436 http://dx.doi.org/10.1159/000360965 |
_version_ | 1782355461244190720 |
---|---|
author | Kim, Changsoo Kim, Min Young Kang, Dae Ryong Kim, Jang-Young Park, Jeong Bae |
author_facet | Kim, Changsoo Kim, Min Young Kang, Dae Ryong Kim, Jang-Young Park, Jeong Bae |
author_sort | Kim, Changsoo |
collection | PubMed |
description | Fimasartan, the eighth angiotensin receptor blocker, was launched in March 2011 and was found to have an excellent efficacy and safety profile in a large cross-sectional population study [Safety and Efficacy of Fimasartan in Patients with Arterial Hypertension (Safe-KanArb); Park et al.: Am J Cardiovasc Drugs 2013;13:47-56]. However, there is no long-term study to evaluate its efficacy for major adverse cardiovascular events (MACE) and other effects. The purpose of this study (K-MetS study) was to evaluate whether the early reduction of blood pressure (BP) and/or correction of metabolic derangements with fimasartan will affect MACE and the development of diabetes after long-term use in patients with hypertension. A total of 10,734 patients were screened between October 2011 and October 2012. Of these, 10,601 patients from 582 private clinics and 11 university hospitals were enrolled and are currently treated with fimasartan. The primary endpoints are MACE (cardiovascular mortality, stroke, myocardial infarction, and hospitalization for heart failure) and the development of diabetes after 3 years of follow-up. In addition to BP monitoring in the clinic, home BP monitoring is performed in about two thirds of patients. The patients were 56.2 ± 10.9 years old (mean ± SD), with 48.4% being women. The mean clinic and home systolic/diastolic BP at baseline were 145.0 ± 17.0/88.8 ± 11.4 and 138.6 ± 14.8/82.6 ± 9.9 mm Hg, respectively. The metabolic syndrome was found in 56.4%, increased abdominal circumference in 52.8%, elevated fasting glucose in 46.8%, hypertriglyceridemia in 44.7%, and low high-density lipoprotein cholesterol in 33.3% of patients. Further, complicated hypertension with diabetes occurred in 15.1%, ischemic heart disease in 3.3%, stroke in 0.9%, heart failure in 0.7%, and atrial fibrillation in 0.4% of patients. Most participants in this study had a low-to-moderate risk for hypertension. The K-MetS study is expected to provide valuable information about the effects of early BP control and correction of metabolic abnormalities on future cardiovascular outcomes relative to low-risk hypertension. |
format | Online Article Text |
id | pubmed-4315348 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-43153482015-11-19 The Efficacy of Fimasartan for Cardiovascular Events and Metabolic Syndrome (K-MetS Study): Rationale, Design and Participant Characteristics Kim, Changsoo Kim, Min Young Kang, Dae Ryong Kim, Jang-Young Park, Jeong Bae Pulse Original Paper Fimasartan, the eighth angiotensin receptor blocker, was launched in March 2011 and was found to have an excellent efficacy and safety profile in a large cross-sectional population study [Safety and Efficacy of Fimasartan in Patients with Arterial Hypertension (Safe-KanArb); Park et al.: Am J Cardiovasc Drugs 2013;13:47-56]. However, there is no long-term study to evaluate its efficacy for major adverse cardiovascular events (MACE) and other effects. The purpose of this study (K-MetS study) was to evaluate whether the early reduction of blood pressure (BP) and/or correction of metabolic derangements with fimasartan will affect MACE and the development of diabetes after long-term use in patients with hypertension. A total of 10,734 patients were screened between October 2011 and October 2012. Of these, 10,601 patients from 582 private clinics and 11 university hospitals were enrolled and are currently treated with fimasartan. The primary endpoints are MACE (cardiovascular mortality, stroke, myocardial infarction, and hospitalization for heart failure) and the development of diabetes after 3 years of follow-up. In addition to BP monitoring in the clinic, home BP monitoring is performed in about two thirds of patients. The patients were 56.2 ± 10.9 years old (mean ± SD), with 48.4% being women. The mean clinic and home systolic/diastolic BP at baseline were 145.0 ± 17.0/88.8 ± 11.4 and 138.6 ± 14.8/82.6 ± 9.9 mm Hg, respectively. The metabolic syndrome was found in 56.4%, increased abdominal circumference in 52.8%, elevated fasting glucose in 46.8%, hypertriglyceridemia in 44.7%, and low high-density lipoprotein cholesterol in 33.3% of patients. Further, complicated hypertension with diabetes occurred in 15.1%, ischemic heart disease in 3.3%, stroke in 0.9%, heart failure in 0.7%, and atrial fibrillation in 0.4% of patients. Most participants in this study had a low-to-moderate risk for hypertension. The K-MetS study is expected to provide valuable information about the effects of early BP control and correction of metabolic abnormalities on future cardiovascular outcomes relative to low-risk hypertension. S. Karger AG 2014-05 2014-04-23 /pmc/articles/PMC4315348/ /pubmed/26587436 http://dx.doi.org/10.1159/000360965 Text en Copyright © 2014 by S. Karger AG, Basel http://www.karger.com/Authors_Choice This is an open access article distributed under the terms of Karger's Author's Choice™ licensing agreement, adapted from the Creative Commons Attribution Non-Commercial 2.5 license. This license allows authors to re-use their articles for educational and research purposes as long as the author and the journal are fully acknowledged. |
spellingShingle | Original Paper Kim, Changsoo Kim, Min Young Kang, Dae Ryong Kim, Jang-Young Park, Jeong Bae The Efficacy of Fimasartan for Cardiovascular Events and Metabolic Syndrome (K-MetS Study): Rationale, Design and Participant Characteristics |
title | The Efficacy of Fimasartan for Cardiovascular Events and Metabolic Syndrome (K-MetS Study): Rationale, Design and Participant Characteristics |
title_full | The Efficacy of Fimasartan for Cardiovascular Events and Metabolic Syndrome (K-MetS Study): Rationale, Design and Participant Characteristics |
title_fullStr | The Efficacy of Fimasartan for Cardiovascular Events and Metabolic Syndrome (K-MetS Study): Rationale, Design and Participant Characteristics |
title_full_unstemmed | The Efficacy of Fimasartan for Cardiovascular Events and Metabolic Syndrome (K-MetS Study): Rationale, Design and Participant Characteristics |
title_short | The Efficacy of Fimasartan for Cardiovascular Events and Metabolic Syndrome (K-MetS Study): Rationale, Design and Participant Characteristics |
title_sort | efficacy of fimasartan for cardiovascular events and metabolic syndrome (k-mets study): rationale, design and participant characteristics |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315348/ https://www.ncbi.nlm.nih.gov/pubmed/26587436 http://dx.doi.org/10.1159/000360965 |
work_keys_str_mv | AT kimchangsoo theefficacyoffimasartanforcardiovasculareventsandmetabolicsyndromekmetsstudyrationaledesignandparticipantcharacteristics AT kimminyoung theefficacyoffimasartanforcardiovasculareventsandmetabolicsyndromekmetsstudyrationaledesignandparticipantcharacteristics AT kangdaeryong theefficacyoffimasartanforcardiovasculareventsandmetabolicsyndromekmetsstudyrationaledesignandparticipantcharacteristics AT kimjangyoung theefficacyoffimasartanforcardiovasculareventsandmetabolicsyndromekmetsstudyrationaledesignandparticipantcharacteristics AT parkjeongbae theefficacyoffimasartanforcardiovasculareventsandmetabolicsyndromekmetsstudyrationaledesignandparticipantcharacteristics AT theefficacyoffimasartanforcardiovasculareventsandmetabolicsyndromekmetsstudyrationaledesignandparticipantcharacteristics AT kimchangsoo efficacyoffimasartanforcardiovasculareventsandmetabolicsyndromekmetsstudyrationaledesignandparticipantcharacteristics AT kimminyoung efficacyoffimasartanforcardiovasculareventsandmetabolicsyndromekmetsstudyrationaledesignandparticipantcharacteristics AT kangdaeryong efficacyoffimasartanforcardiovasculareventsandmetabolicsyndromekmetsstudyrationaledesignandparticipantcharacteristics AT kimjangyoung efficacyoffimasartanforcardiovasculareventsandmetabolicsyndromekmetsstudyrationaledesignandparticipantcharacteristics AT parkjeongbae efficacyoffimasartanforcardiovasculareventsandmetabolicsyndromekmetsstudyrationaledesignandparticipantcharacteristics AT efficacyoffimasartanforcardiovasculareventsandmetabolicsyndromekmetsstudyrationaledesignandparticipantcharacteristics |